Start here if you're new
what it is
Crocs sells foam clogs, sandals, charms, and casual shoes through stores, wholesalers, and its own websites in more than 90 countries.
how it gets paid
Last year Crocs made $4.0B in revenue. Crocs clogs was the main engine at $2.2B, or 55% of sales.
why growth slowed
Revenue fell 1.5% last year. Full-year revenue was $4.0B, down 1.5% vs. prior year, according to SEC filings.
what just happened
Crocs posted EPS of $2.03, beating the $1.85 estimate by 9.73%, but the brand mix still did the stock no favors.
At a glance
B+ balance sheet — decent shape, but not bulletproof
25/100 earnings predictability — expect surprises
7.1x trailing p/e — the market's not buying it — or you found a deal
23.0% return on capital — every dollar works hard here
xvary composite: 63/100 — average
What they do
Crocs sells foam clogs, sandals, charms, and casual shoes through stores, wholesalers, and its own websites in more than 90 countries.
Crocs wins because you can spot the product from across a parking lot, and that matters in footwear where sameness is the default. The company has sold more than 630 million pairs, and 44% of 2024 sales came from outside the U.S., which tells you the brand travels. Proprietary Croslite material is product differentiation → a distinct feel and look → so you are not just buying another cheap sandal.
How they make money
$4.0B
annual revenue · their business grew -1.5% last year
Crocs clogs
$2.2B
+2.0%
HEYDUDE casual shoes
$0.8B
10.0%
Sandals
$0.5B
+8.0%
Jibbitz accessories
$0.2B
+6.0%
Sneakers and other footwear
$0.3B
+1.0%
The products that matter
iconic foam clog sales
Classic Clog
$2.0B · roughly half of revenue
it's the core product driving roughly $2.0B of the company's $4.0B in annual sales. when one shoe accounts for about half the business, product relevance is the investment case.
core driver
sales outside the home market
International sales
$2.0B · 50% of revenue
this side of the business contributes $2.0B, or 50% of total sales. that gives you growth runway, but it also means half the revenue base depends on execution outside the domestic market.
half the business
sales in the home market
Domestic sales
$2.0B · 50% of revenue
the domestic business is also $2.0B, or 50% of revenue. same split. same starting point. the question is which side gets back to growth first.
stability check
Key numbers
7.1x
trailing p/e
P/E → how many dollars you pay for one dollar of earnings → so what: Crocs is priced like earnings are about to break.
23.0%
return on capital
Return on capital → profit generated from money invested in the business → so what: this is far above what most retailers manage.
$1.3B
long-term debt
Debt → money the company owes → so what: HEYDUDE has less room to disappoint when leverage is still this large.
59.5%
gross margin
Gross margin → what is left after making the product → so what: the foam shoe business is weirdly lucrative.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 15 / 100
- long-term debt $1.3B (23% of capital)
- net profit margin 15.4% — keeps 15 cents of every dollar in revenue
- return on equity 32% — $0.32 profit for every $1 investors have put in
B+ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in CROX 3 years ago → it's now worth $7,780.
The index would have given you $14,770.
source: institutional data · total return
What just happened
beat estimates
Crocs posted EPS of $2.03, beating the $1.85 estimate by 9.73%, but the brand mix still did the stock no favors.
Full-year revenue was $4.0B, down 1.5% vs. prior year, according to SEC filings. The core Crocs brand held up better than HEYDUDE, which remained the clear weak spot.
$4.0B
revenue
$2.03
eps
59.5%
gross margin
the number that mattered
The number that mattered was the 22% drop in HEYDUDE Q3 receipts to $160M, because that is the part of the story keeping the multiple stuck at 7.1x.
-
a primary reason for the weakness is due to the heydude brand.
-
in fact, that business has been a large headwind for crocs ever since the acquisition.
-
third-quarter results indicated that heydude receipts shrank 22%, vs. prior year, to $160 million.
-
moreover, the period highlighted weakness within the core brand, as crocs sales were down 2.5%, over the same span, to $836 million.specifically, demand was weak in the u.s., but international strength was shown in regions like china, japan, and western europe.
-
elsewhere, profitability was dampened by tariffs, product mix shifts, and higher operating costs.nonetheless, the company’s strong cash generation allowed $203 million in share repurchases and $63 million in debt reduction, which supported share earnings. overall, september-period results were better than feared, as we had looked for sales and share earnings of $960 million and $2.35, respectively.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is classic clog fatigue.
high
classic clog concentration
roughly $2.0B of annual sales appears tied to one product. if the core silhouette loses relevance, the revenue line feels it fast.
about half of the $4.0B revenue base is exposed
high
discretionary spending pullback
this is footwear, not a utility bill. when consumers cut back, delaying a pair of clogs is easy.
nearly all $4.0B in annual revenue depends on optional spending
med
international execution
international sales are $2.0B, or 50% of revenue. that gives you reach and execution risk in the same package.
half of revenue sits outside the domestic market
med
debt matters more in a slowdown
$1.3B of long-term debt is manageable in a healthy business. it matters more when revenue is already down 1.5% and the next quarter is expected to be weaker.
long-term debt equals 23% of capital
roughly half of crocs' revenue appears tied to one product, half comes from outside the domestic market, and nearly all of the $4.0B business depends on discretionary spending. that is a profitable setup, not a protected one.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
whether revenue gets back above zero
sales fell 1.5% last year, and the next quarter is expected to be down 6%. the rerating starts with stabilization, not with story time.
risk
classic clog relevance
roughly $2.0B of sales comes from the core clog. if product buzz cools, you will see it in the revenue mix before you hear it on the call.
calendar
the next earnings print
the street expects $1.85 EPS on $1.0B revenue. beating that matters less than showing the decline is flattening.
trend
institutional selling versus accumulation
3q2025 showed 227 buyers against 266 sellers. if that flips, you may be seeing confidence return before the headline numbers do.
Analyst rankings
short-term outlook
top 20%
momentum score 2 — analysts expect above-average price performance in the year ahead. in human-speak, they think the stock has room to recover even before the business looks clean.
risk profile
average
stability score 3 — average risk on paper, even if the 15 / 100 price stability score says the ride can still feel rough.
chart momentum
average
technical score 3 — no extreme signal. the chart is not rescuing the thesis, and it is not killing it either.
earnings predictability
25 / 100
earnings can swing around more than you want. for you, that means quarter-to-quarter noise is part of the package.
source: institutional data
Institutional activity
227 buyers vs. 266 sellers in 3q2025. total institutional holdings: 49.6M shares.
source: institutional data
Price targets
3-5 year target range
$56
$151
$86
current price
$104
target midpoint · +22% from current · 3-5yr high: $165 (+95% · 18% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive